Q3/9M 2025 Revenue

Revenue up 11.7% in the third quarter

Best quarterly performance ever for the Group

• Group’s revenue +11.7% in the third quarter at constant exchange rates¹, +8.8% in the nine months

• Wearables major boost, enlarging the portfolio with a strong pipeline of product innovation
• Vision care and sunglasses growing 5% at constant exchange rates¹ and perimeter

• North America and EMEA up double digits in both PS and DTC channels
• Stellest supported by strong clinical results, “de novo” fully approved by FDA, in the US market from October
• RetinAI acquisition announced yesterday. Optegra closed, to be consolidated as of October, 1